» Authors » Andreas Lechner

Andreas Lechner

Explore the profile of Andreas Lechner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 76
Citations 1124
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Nowotny H, Zheng T, Seiter T, Ju J, Schneider H, Kroiss M, et al.
Front Immunol . 2025 Jan; 15:1428054. PMID: 39749333
Background: High dietary sodium intake is a major cardiovascular risk factor and adversely affects blood pressure control. Patients with primary aldosteronism (PA) are at increased cardiovascular risk, even after medical...
2.
Harada S, Gersing A, Stohldreier Y, Dietrich O, Lechner A, Seissler J, et al.
Front Endocrinol (Lausanne) . 2024 Jan; 14:1303126. PMID: 38292769
Background And Objective: Fat content in bones and muscles, quantified by magnetic resonance imaging (MRI) as a proton density fat fraction (PDFF) value, is an emerging non-invasive biomarker. PDFF has...
3.
Pappa E, Busygina K, Harada S, Hermann H, Then C, Lechner A, et al.
BMJ Open Diabetes Res Care . 2024 Jan; 12(1). PMID: 38199777
Introduction: Women with a history of gestational diabetes mellitus (GDM) are at high risk of developing type 2 diabetes, while the exact mechanisms underlying its pathophysiology are still unclear. We...
4.
Sandforth A, von Schwartzenberg R, Arreola E, Hanson R, Sancar G, Katzenstein S, et al.
Lancet Diabetes Endocrinol . 2023 Sep; 11(11):798-810. PMID: 37769677
Background: Remission of type 2 diabetes can occur as a result of weight loss and is characterised by liver fat and pancreas fat reduction and recovered insulin secretion. In this...
5.
Schneider H, Sarkis A, Sturm L, Britz V, Lechner A, Potzel A, et al.
J Intern Med . 2023 Mar; 294(1):47-57. PMID: 36945842
Background: Primary aldosteronism (PA) is a frequent cause of hypertension. Aldosterone excess together with high dietary salt intake aggravates cardiovascular damage, despite guideline-recommended mineralocorticoid receptor antagonist (MRA) treatment. Objectives: To...
6.
Hummel M, Fuchtenbusch M, Battefeld W, Buhrer C, Groten T, Haak T, et al.
Exp Clin Endocrinol Diabetes . 2023 Jan; 131(1-02):4-12. PMID: 36626920
No abstract available.
7.
Lau L, Nano J, Prehn C, Cecil A, Rathmann W, Zeller T, et al.
Front Endocrinol (Lausanne) . 2023 Jan; 13:1000650. PMID: 36601008
Introduction: The role of endogenous androgens in kidney function and disease has not been extensively explored in men and women. Research Design And Methods: We analyzed data from the observational...
8.
Kern-Matschilles S, Gar C, Schilbach K, Haschka S, Rauch B, Then C, et al.
Horm Metab Res . 2022 May; 54(9):613-619. PMID: 35556239
Recently, we proposed two pathophysiologic subtypes of type 2 diabetes mellitus (T2DM), one related and one unrelated to metabolic syndrome. To begin to understand the pathophysiology of the subtype unrelated...
9.
Haschka S, Gar C, Potzel A, Sacco V, Kern-Matschilles S, Benz I, et al.
Cureus . 2022 May; 14(4):e23916. PMID: 35530849
Background/objective Type 2 diabetes related to metabolic syndrome is often partially reversible after weight loss. We conducted a pilot trial on whether complete remission to the point of a normalized...
10.
Lechner A
MMW Fortschr Med . 2022 May; 164(9):36-39. PMID: 35513664
No abstract available.